DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for aggressive lymphoma: targeted drug combo under study
Disease control Recruiting nowThis early-phase study tests whether adding the targeted drug polatuzumab vedotin (with or without another drug, glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to see how well …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 09:02 UTC
-
New CAR T-Cell therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis trial tests a new CAR T-cell therapy called WZTL-002 in 60 people with large B-cell lymphoma that has returned or not responded to standard chemotherapy. Participants receive their own modified immune cells to attack the cancer, and doctors will check how many achieve comple…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated May 26, 2026 08:20 UTC
-
New combo therapy hopes to boost lymphoma treatment
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 participants will receive the combination as their first treatment. The goal is to improve cancer remissi…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New Three-Drug cocktail aims to tackle tough lymphoma
Disease control Recruiting nowThis early-phase trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) in about 30 adults with diffuse large B-cell lymphoma that has come back or not responded to prior therapy. The main goal is to find the safest dose and see if the com…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Blood test may let some lymphoma patients skip extra chemo
Knowledge-focused Recruiting nowThis study looks at whether a new blood test (ctDNA) can guide doctors to safely give less chemotherapy to certain patients with a type of lymphoma called DLBCL. About 40 newly diagnosed patients will have their blood tested during standard treatment. If the test shows no cancer …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: NA • Sponsor: Hua-Jay J Cherng, MD • Aim: Knowledge-focused
Last updated May 26, 2026 08:32 UTC